Discover
KROS
Keros Therapeutics, Inc.
10.88
2 x 7.76
2 x 13.65
bid
ask
+
0.18
1.68%
2 @ 04:00 PM
10.88 +0.00 (0.00%)
| Ytd | -46.56% | |
| 1y | -18.44% |
10.60
day range
10.94
9.69
52 week range
22.55
| Open | 10.70 | Prev Close | 10.70 | Low | 10.60 | High | 10.94 | Mkt Cap | 215.34M |
| Vol | 209.95K | Avg Vol | 324.86K | EPS | -2.53 | P/E | N/A | Forward P/E | -3.00 |
| Beta | 1.24 | Short Ratio | 5.28 | Inst. Own | 100.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 10.96 | 200-d Avg | 14.78 | 1yr Est | 43.55 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-06 | 2024-09 | -1.26 | -1.41 | -0.15 | -11.90% |
| 2024-08-07 | 2024-06 | -1.23 | -1.25 | -0.02 | -1.63% |
| 2024-08-07 | 2024-06 | -1.23 | N/A | N/A | N/A |
| 2024-05-08 | 2024-03 | -1.31 | N/A | N/A | N/A |
| 2024-05-08 | 2024-03 | -1.31 | -1.21 | 0.1 | 7.63% |
| 2024-02-28 | 2023-12 | -1.38 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-23 | Truist Securities | Upgrade | Buy | Buy |
| 2024-12-16 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-12-16 | Guggenheim | Downgrade | Buy | Neutral |
| 2024-12-13 | Scotiabank | Upgrade | Sector Outperform | Sector Outperform |
| 2024-12-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-12 | William Blair | Downgrade | Outperform | Market Perform |
Profile
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-08-12 | GORDON CARL L | Director | 0.00 | Sale |
| 2024-08-12 | ORBIMED ADVISORS, L.L.C. | Unknown | 0.00 | Sale |
| 2023-11-02 | REGNANTE KEITH C | Chief Financial Officer | 0.00 | Conversion of Exercise of derivative security |
| 2023-04-06 | SEEHRA JASBIR | Chief Executive Officer | 252.86K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | FMR, LLC | 4.90M | 83.87M | 12.09% |
| 2024-09-29 | Blackrock Inc. | 2.63M | 45.07M | 6.50% |
| 2024-09-29 | Alkeon Capital Management LLC | 1.90M | 32.49M | 4.68% |
| 2024-09-29 | Vanguard Group Inc | 1.86M | 31.78M | 4.58% |
| 2024-09-29 | Darwin Global Management, Ltd. | 1.52M | 26.09M | 3.76% |
| 2024-09-29 | Price (T.Rowe) Associates Inc | 1.51M | 25.93M | 3.74% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 961.35K | 16.46M | 2.37% |
| 2024-09-29 | ACAP Strategic Fund | 933.99K | 15.99M | 2.31% |
| 2024-09-29 | Price (T.Rowe) New Horizons Fund | 877.88K | 15.03M | 2.17% |
| 2024-10-30 | iShares Russell 2000 ETF | 756.55K | 12.95M | 1.87% |
| 2024-10-30 | Fidelity Select Portfolios - Biotechnology | 661.23K | 11.32M | 1.63% |
| 2024-10-30 | Fidelity Select Portfolios - Health Care | 650.00K | 11.13M | 1.60% |